NCT07471607Completed
Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes
Efficacy and Safety of Overripe Banana as an Adjunct to Specific Diabetic Formulas in Type 2 Diabetes Mellitus: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 13 Mar 2026
Brief summary (registry, in English)
This randomized controlled clinical trial aims to evaluate the effects of overripe banana powder supplementation on metabolic parameters among patients with type 2 diabetes mellitus (T2DM). Dietary management plays a crucial role in glycaemic control for individuals with T2DM, and the identification of functional food ingredients with potential metabolic benefits has gained increasing research interest. Overripe banana contains various bioactive compounds including resistant starch, dietary fiber, and polyphenols, which may contribute to improved glycaemic regulation and metabolic outcomes. Participants diagnosed with T2DM will be randomly assigned to receive either a nutritional intervention or control supplementation for a defined intervention period. The intervention involves daily consumption of a measured dose of overripe banana powder incorporated into the participants' diet. Clinical and biochemical parameters will be assessed at baseline and after the intervention period to evaluate potential metabolic changes. Primary outcomes include indicators of glycaemic control such as fasting blood glucose and glycated hemoglobin (HbA1c). Secondary outcomes include changes in blood pressure and other metabolic parameters. The findings of this study may provide evidence on the potential role of overripe banana-derived functional ingredients as a dietary strategy for improving metabolic health among individuals with T2DM.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 6 Mar 2026
- Start date
- 1 Mar 2025
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- Universiti Sains Malaysia
- Diseases
- Type 2 diabetes
- NCT number
- NCT07471607
What you commit to
- Study type: Interventional
- Participants enrolled: 60
- From 1 Mar 2025 to the primary completion date, 30 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals receiving insulin therapy
Other illness
- History of drug or alcohol abuse
- Serious mental disorders
- Presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, or infectious diseases that may interfere with study participation
Other
- Pregnant or lactating women
Who the study is looking for
- Adults aged ≥18 years diagnosed with Type 2 Diabetes Mellitus (T2DM)
- HbA1c between 6.5% and 10% at baseline
- Fasting blood glucose \<15 mmol/L
- Body mass index (BMI) ≥23 kg/m²
- Non-insulin-dependent T2DM
- On a stable antidiabetic medication regimen for at least 3 months prior to enrolment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universiti Sains Malaysia Coordinator of this site? Confirm its status | Kubang Kerian | Malaysia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.